Clinical trialNARecruiting
Becotatug Vedotin Plus Anti-PD-1 and S-1 in Patients With EGFR-Positive Advanced Pancreatic Cancer Who Have Failed at Least One Line of Standard Therapy
- Outcome
- Ongoing
- Phase
- NA
- Status
- Recruiting
- Study type
- Interventional
- Start
- 7 October 2026
- Expected end
- 1 February 2028
- Enrollment
- 27 participants
- Sites
- 1
- Primary outcomes
- Objective Response Rate (ORR)
- Sponsor
- Other gov
- Results posted
- No
- Last update
- 23 October 2026
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try